company background image
AXGN logo

Axogen NasdaqCM:AXGN Stock Report

Last Price

US$13.73

Market Cap

US$596.5m

7D

-2.9%

1Y

222.7%

Updated

09 Oct, 2024

Data

Company Financials +

AXGN Stock Overview

Develops and commercializes technologies for peripheral nerve regeneration and repair worldwide.

AXGN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Axogen, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Axogen
Historical stock prices
Current Share PriceUS$13.73
52 Week HighUS$15.08
52 Week LowUS$3.45
Beta1.13
11 Month Change5.45%
3 Month Change64.83%
1 Year Change222.68%
33 Year Change-1.44%
5 Year Change12.08%
Change since IPO406.64%

Recent News & Updates

Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely

Sep 14
Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely

Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?

Aug 20
Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?

Recent updates

Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely

Sep 14
Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely

Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?

Aug 20
Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?

A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb

Jul 29
A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost

Jun 12
Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost

Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?

Apr 16
Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?

Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Mar 28
Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

Jan 26
Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt

Sep 10
We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt

Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues

Aug 09
Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues

AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?

Jan 13
AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?

Is AxoGen (NASDAQ:AXGN) A Risky Investment?

Sep 10
Is AxoGen (NASDAQ:AXGN) A Risky Investment?

AxoGen: Investors Are Positioned Long Leading Into Q2 FY22 Earnings

Aug 02

Axogen estimates Q2 revenue above consensus, reaffirms guidance

Jul 18

Shareholder Returns

AXGNUS Medical EquipmentUS Market
7D-2.9%-0.7%0.6%
1Y222.7%19.4%30.3%

Return vs Industry: AXGN exceeded the US Medical Equipment industry which returned 19.4% over the past year.

Return vs Market: AXGN exceeded the US Market which returned 30.3% over the past year.

Price Volatility

Is AXGN's price volatile compared to industry and market?
AXGN volatility
AXGN Average Weekly Movement11.7%
Medical Equipment Industry Average Movement8.6%
Market Average Movement6.4%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market3.2%

Stable Share Price: AXGN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: AXGN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a427n/awww.axogeninc.com

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.

Axogen, Inc. Fundamentals Summary

How do Axogen's earnings and revenue compare to its market cap?
AXGN fundamental statistics
Market capUS$596.52m
Earnings (TTM)-US$16.54m
Revenue (TTM)US$173.48m

3.5x

P/S Ratio

-36.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AXGN income statement (TTM)
RevenueUS$173.48m
Cost of RevenueUS$35.79m
Gross ProfitUS$137.69m
Other ExpensesUS$154.23m
Earnings-US$16.54m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.38
Gross Margin79.37%
Net Profit Margin-9.53%
Debt/Equity Ratio51.7%

How did AXGN perform over the long term?

See historical performance and comparison